



Shortage of EpiPen®

EpiPen® and EpiPen® Junior (adrenaline auto-injector devices) will be subject to limited availability for the remainder of 2018. Mylan are currently (September 2018) out-of-stock

of EpiPen® Junior, with continued interruptions in supply anticipated in the coming months.

Information about the supply situation, as well as recommended courses of action to help manage the consequences is available from the [SPS website](#). This link has been added to the EpiPen® entry in the Tayside Area Formulary (TAF).

Further information can be found in [Tayside Prescriber 152](#).

Diabetes Formulary Updates

The Tayside Diabetes MCN Handbook section on [Treatment with Insulin](#) has been updated and the Tayside Area Formulary has been updated to reflect the changes.

The Tayside Area Formulary and this section of the Diabetes Handbook relate to treatment in **adults only**.

Changes include:

Insulin as Combination Therapy

This strategy is most often used for obese type 2 patients after consultation with the specialist diabetes team.

Once daily liraglutide remains the GLP-1 receptor agonist of choice in NHS Tayside. For patients who prefer a once weekly injection, dulaglutide (Trulicity®▼) can be considered. This is now the first choice **once weekly** GLP-1 receptor agonist in NHS Tayside.

Dulaglutide (Trulicity®▼) is a similar cost to once weekly exenatide (Bydureon®) but can be used at a lower eGFR in comparison to exenatide (Bydureon®).

Insulin Preparations

The [insulin preparations](#) table (for treatment in adults) in the

Diabetes Handbook has been updated to reflect current preparations prescribed, including newer preparations:

- Abasaglar®▼ (insulin glargine 100units/mL) – now 1st line basal insulin (replacing Lantus® for new patients) in type 1 diabetes and now 2nd line basal insulin if nocturnal hypoglycaemia with isophane insulin in type 2 diabetes
- Toujeo® (insulin glargine 300units/mL) – now 2nd line basal insulin if requiring high doses of isophane insulin/ nocturnal hypoglycaemia in type 2 diabetes or 3rd line basal insulin if ongoing nocturnal hypoglycaemia with insulin glargine 100units/mL in type 2 diabetes

The Tayside Area Formulary does not list individual insulin preparations as this information is included in the insulin preparations table in the Diabetes Handbook.

Insulin must be prescribed by brand name. High concentration insulins (e.g. Toujeo®) are initiated by specialists as they **are not interchangeable without dosage adjustment.**



MHRA Drug Safety Update

Valproate Pregnancy Prevention Programme

[September's Drug Safety Update](#) reminds healthcare professionals of the actions required if prescribing valproate for women of child bearing potential and the requirements of the Pregnancy Prevention Programme.

Childrens' Hospital at Ninewells

There is now a link to the [Tayside Children's Hospital website](#) (intranet link only) from [Chapter 23: Useful links](#) from the Tayside Area Formulary.

Emollients Formulary Update

The emollients section of the formulary has been updated. The key points to note are:

- Recommendation to use lower cost leave-on emollients
- Removal of Dermalol® preparations
- Removal of bath additives

Further information including a table of the new formulary emollients, can be found in the recently published [Tayside Prescriber Issue 151 Emollient Formulary Update](#).

Further changes not outlined in the above bulletin include:

- QV® intensive ointment, Diprobase® lotion, Eucerin® (10% urea) Intensive lotion, and Emulsifying ointment – now non-formulary
- All spray emollients now non-formulary (Emollin® and Dermamist®)
- ImuDerm® (urea 5%, glycerol 5%) cream added to formulary



For full information on any of the drugs listed below use the link to the Scottish Medicines Consortium (SMC) website below to search by generic, brand or SMC no.
See NHS Tayside 'Local Decisions on SMC Advice' database (link below) for full details on Board decisions - these are currently listed alphabetically by page.

SMC Advice

Published 10th September 2018

Bictegravir 50mg / emtricitabine 200mg / tenofovir alafenamide 25mg film-coated tablet (Biktarvy®) SMC2093

Dolutegravir 50mg / rilpivirine 25mg film-coated tablets (Juluca®) SMC2091

Dupilumab 300mg solution for injection in pre-filled syringe (Dupixent®) SMC2011

Tocilizumab, 162mg solution for injection in pre-filled syringe and pre-filled pen (RoActemra®) SMC2014

SMC 'Not recommended' medicines - September 2018

Denosumab 60mg solution for injection in pre-filled syringe (Prolia®) SMC2117

Obinutuzumab, 1,000mg, concentrate for solution for infusion (Gazyvaro®) SMC2015

Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC No 1339/18

New & Updated Formulary Links

- [SIGN 155 Pharmacological management of migraine, February 2018](#)
- [GP, Community Nurse and Specialist Nurse Oral Nutritional Supplement \(ONS\) Formulary for Adults](#)
- [GP, Community Nurse and specialist Nurse Oral Nutritional Supplement Prescribing Guidelines for Adults](#)
- [Management of Acne – first line treatments algorithm](#) (to be used with [Management of Acne guidance notes](#)).

Other Formulary Updates

- Frovatriptan added to formulary (Green traffic light) for prophylaxis of perimenstrual migraine from two days before until three days after bleeding starts [off-label]
- Sodium fluoride 1.1% (5000ppm) toothpaste added to formulary (Amber traffic light). Restricted to prescribing by GPs under the direction of a Dentist/Dental hospital/ENT/Oral Maxillo Facial Surgery/Oncology/Radiotherapy specialists to prevent dental caries and reduce the risk of osteoradionecrosis in patients with head and neck cancer/oral cancer/undergoing head and neck radiotherapy
- Hydroxycarbamide added to formulary (Amber traffic light) for myeloproliferative disorders under the direction of Haematology
- Biosimilar rituximab (Truxima®) now on formulary for Renal & Rheumatology indications
- [Renal specialist formulary list](#) updated following formulary review

Links to Additional Information

Monthly Drug Safety Updates:

www.gov.uk/government/publications/drug-safety-update-monthly-newsletter

For full details of medicines and forthcoming SMC Advice see SMC Website:

www.scottishmedicines.org.uk

For a Summary of a Product's Characteristics (SPCs) see Electronic Medicines Compendium Website:

<http://www.medicines.org.uk/emc/>

For full details on NHS Board decisions see Tayside Area Formulary - Local Decisions on SMC Advice database:

<http://www.nhstaysideadtc.scot.nhs.uk/approved/formular/NewMedsHomepage.htm>

Local implementation of SMC recommendations is taken forward by the Tayside Prescribing Support Unit (PSU). This bulletin is based on evidence available to Tayside PSU at time of publication and is covered by the Disclaimer and Terms & Conditions of Use.

Medicines within the Tayside Area Formulary are intended to guide choice on a rational selection of medicines for **adults** which have been included on the basis of clinical efficacy, safety, patient acceptability and cost-effectiveness.

This bulletin is produced by the Medicines Advisory Group (MAG), which is a sub-group of the NHS Tayside Area Drug and Therapeutics Committee. Please direct any queries to:

Hazel Steele, Lead Pharmacist, Prescribing Support
E-mail: hazelsteele@nhs.net

Claire James, Senior Pharmacist - Clinical Effectiveness
E-mail: clairejames@nhs.net

Karen Harkness, Principal Pharmacist, Clinical Effectiveness
E-mail: kharkness@nhs.net

Local processes exist to allow prescribing of non-SMC approved medicines for individual patients and are available in the [Policy on Prescribing of Non-Formulary Medicines \(including PACS Tier 1 & 2\)](#)